中国加强对国际制药企业的监管

choi

Katie Thomas, 中国加强对国际制药企业的监管. 纽约时报中文网. July 17, 2013
http://cn.nytimes.com/china/20130717/c17drug/

, which is translated from

Katie Thomas, For Global Drug Manufacturers, China Becomes a Perilous Market; New scrutiny for practices once found acceptable. New York Times, July 17, 2013

the first three paragraphs:

"Global drug companies now employ more sales people in China than they do in the United States, their largest market. Several, including Merck and GlaxoSmithKline, are making huge scientific investments in the country, including building research and development centers. Within the next few years, China is poised to surpass Japan as the world’s second-largest pharmaceutical market.

"The booming Chinese demand for drugs couldn’t come at a better time for Western manufacturers, whose sales have been slumping because of patent expirations in the United States and stringent price controls in Europe.

"But selling pharmaceuticals and other health care products in China is increasingly fraught with peril, as shown by allegations in China this week that GlaxoSmithKline funneled payments through travel agents to doctors, hospitals and government officials to bolster drug sales in the country.

My comment:
(a) The home page of 纽约时报中文网 heralds the translation with "中国审查在华制药企业; 外国公司面临新一轮政府监管风险."
(b) There is no need to read the rest.